고형암 (전체)

9개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved9 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleMerckApproved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1669Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

trastuzumab (Herceptin, Ogivri, Herzuma)

HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma · HER2

#HER2#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1100Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
ADCCurated CoreFDAstaleDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, TDxd)

HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow brea… · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 243Status Approved
AntibodyCurated CoreFDAstaleBeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
ADCCurated CoreFDAstaleAstellasMMAE (monomethyl auristatin…Approved

enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv)

Locally advanced or metastatic urothelial carcinoma · Nectin-4

#Nectin-4#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 201Status Approved
AntibodyCurated CoreFDAstaleJazz PharmaceuticalsApproved

zanidatamab (Ziihera, ZW25, zanidatamab-hrii)

First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract can… · HER2 (biparatopic)

#HER2biparatopic#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 35Status Approved
AntibodyCurated CoreFDAstaleAstellasApproved

zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab)

CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma · CLDN18.2 (claudin-18.2)

#CLDN182claudin-182#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 26Status Approved
ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved